{
  "completed": true,
  "status": "completed_original_source_reconciliation",
  "provider_mode": "Consensus Pro signed-in browser; observed response and citation-link mappings",
  "queries": [
    "https://consensus.app/search/mesolimbic-dopamine-schizophrenia/O4UuYpiZT8uZvOsbnNLBXQ/"
  ],
  "query_record_note": "Observed thread URL and visible request/response in raw receipt; no unobserved query payload reconstructed.",
  "primary_comparison_count": 4,
  "primary_comparisons": [
    {
      "pmid": "21768612",
      "doi": "10.1176/appi.ajp.2011.11010160",
      "source_type": "primary study report",
      "study_group": "PMID21768612",
      "access_depth": "full_text_partial",
      "consensus_aspect": "Dopamine abnormalities precede some psychosis transitions.",
      "result_comparison": "Original prospective study body supports a striatal association in a small converter group. The limbic comparison is nonsignificant; a prospective association is not a selective mesolimbic necessity test.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/21768612/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_remaining_priority_06_10_2026-10-09\\dopamine-schizophrenia\\examinations\\resumption-34-51-1400.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_remaining_priority_06_10_2026-10-09\\dopamine-schizophrenia\\body-presentation-receipts\\21768612-s1-p2-5.json",
        "deliverables\\hsef_v53_remaining_priority_06_10_2026-10-09\\dopamine-schizophrenia\\body-presentation-receipts\\21768612-s2-p3-4.json"
      ]
    },
    {
      "pmid": "32910150",
      "doi": "10.1093/schbul/sbaa128",
      "source_type": "primary study report",
      "study_group": "PMID32910150",
      "access_depth": "full_text_partial",
      "consensus_aspect": "Treatment resistance can distinguish dopamine-related illness.",
      "result_comparison": "Original multicentre STRATA body finds no responder/nonresponder dopamine difference. A settled diagnostic classifier cannot be inferred from earlier small studies.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/32910150/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_remaining_priority_06_10_2026-10-09\\dopamine-schizophrenia\\examinations\\resumption-0-17-1050.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_remaining_priority_06_10_2026-10-09\\dopamine-schizophrenia\\body-presentation-receipts\\32910150-s1-p3-4.json",
        "deliverables\\hsef_v53_remaining_priority_06_10_2026-10-09\\dopamine-schizophrenia\\body-presentation-receipts\\32910150-s2-p11.json"
      ]
    },
    {
      "pmid": "38691387",
      "doi": "10.1001/jamapsychiatry.2024.0785",
      "source_type": "primary study report",
      "study_group": "PMID38691387",
      "access_depth": "full_text_partial",
      "consensus_aspect": "Muscarinic treatment can improve psychotic symptoms.",
      "result_comparison": "Original EMERGENT-3 body verifies registration and a positive PANSS endpoint, but excludes treatment-resistant history and does not measure a selective dopamine mediator. It does not establish efficacy in TRS or dopamine dispensability.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/38691387/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_remaining_priority_06_10_2026-10-09\\dopamine-schizophrenia\\examinations\\resumption-0-17-1050.json"
      ],
      "body_receipts": [
        "deliverables\\hsef_v53_remaining_priority_06_10_2026-10-09\\dopamine-schizophrenia\\body-presentation-receipts\\38691387-s1-p0-1-4-5.json",
        "deliverables\\hsef_v53_remaining_priority_06_10_2026-10-09\\dopamine-schizophrenia\\body-presentation-receipts\\38691387-s2-p7.json"
      ]
    },
    {
      "pmid": "10739409",
      "doi": "10.1176/appi.ajp.157.4.514",
      "source_type": "primary study report",
      "study_group": "PMID10739409",
      "access_depth": "abstract_metadata",
      "consensus_aspect": "D2 occupancy supports a symptom-treatment relationship.",
      "result_comparison": "Original primary abstract links occupancy to clinical response and adverse effects. This bounded audit does not verify a preregistered selective mesolimbic mediator/trajectory experiment; failure to verify that provenance is not failure of antipsychotic efficacy.",
      "original_source": "https://pubmed.ncbi.nlm.nih.gov/10739409/",
      "source_examination_receipts": [
        "deliverables\\hsef_v53_remaining_priority_06_10_2026-10-09\\dopamine-schizophrenia\\examinations\\resumption-0-17-1050.json"
      ],
      "body_receipts": []
    }
  ],
  "grade_changed": false,
  "grade_change_note": "Comparison does not introduce an independently blinded regrade; bounded case adjudication remains source-based.",
  "raw_receipts": [
    {
      "path": "deliverables\\hsef_v53_remaining_priority_06_10_2026-10-09\\dopamine-schizophrenia\\consensus-browser-2026-10-11.json",
      "sha256": "11361cfb53ec17ecdefdec07e364ad532090ed879010e870ca4262f3db59ab4a"
    }
  ],
  "independent_blinded_audit": false,
  "cutoff": "2026-10-09",
  "completed_utc": "2026-10-12T02:11:33.494044+00:00",
  "conclusion": "Specific qualifiers and endpoint hierarchy above are retained in the evidence cards; AI wording does not override the original sources."
}